FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)
-
-
-
-
-
-
-
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
-
-
-
-
-
-
-
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
-
-
-
-
-
-
-
Zymeworks outlines 2026 strategy with potential $440M milestones
-
-
-
-
-
-
-
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
-
-
-
-
-
-
-
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
-
-
-
-
-
-
-
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

